Tiprelestat added to PAH treatment (Phase 2)
Part of Lungs & breathing clinical trials.
This trial tests whether adding a new drug called tiprelestat to standard pulmonary arterial hypertension (PAH) treatments can help patients breathe better and feel stronger. You'd receive tiprelestat or placebo along with your current PAH medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years
- Diagnosed with WHO Group I pulmonary arterial hypertension (PAH)
- Currently taking at least one PAH medication (like sildenafil, bosentan, riociguat, or prostacyclin) plus Sotatercept, all stable for required time periods
- Recent heart catheterization showing specific pressure and resistance readings in your lungs
- Can walk 100–500 meters in 6 minutes
- Willing to use contraception if of childbearing potential, and not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if treprostinil can help people with pulmonary arterial hypertension (PAH) who are at intermediate risk. You may join if you have been diagnosed with certain types of PAH and meet specific heart and lung test results.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This study looks at how well the drug Treprostinil works in people with a specific type of pulmonary hypertension (high blood pressure in the lungs). It helps researchers understand real-world results and side effects.
This trial tests a combination of three medications (an endothelin receptor antagonist, a PDE5 inhibitor, and sotatercept) as the first treatment for people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to see if starting with all three together works better than the usual approach.
This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.
This study tests whether changing from the oral medicine selexipag to an inhaled treatment called treprostinil (LIQ861) can improve symptoms or be better tolerated in adults with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs. If you are currently taking selexipag but it isn't working well enough or causes side effects, this switch might be a good option for you.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.